8,233 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Acquired by Rhumbline Advisers

Rhumbline Advisers purchased a new stake in Eliem Therapeutics, Inc. (NASDAQ:ELYM) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 8,233 shares of the company’s stock, valued at approximately $59,000.

Separately, Bank of New York Mellon Corp acquired a new position in Eliem Therapeutics during the 2nd quarter worth approximately $134,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Eliem Therapeutics Trading Up 2.2 %

Shares of ELYM stock opened at $5.09 on Tuesday. The firm has a fifty day simple moving average of $7.09 and a two-hundred day simple moving average of $6.56. Eliem Therapeutics, Inc. has a 12 month low of $2.35 and a 12 month high of $11.55. The firm has a market capitalization of $151.44 million, a PE ratio of -9.60 and a beta of -0.35.

Eliem Therapeutics (NASDAQ:ELYM) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($1.81) earnings per share for the quarter.

Insider Activity

In other news, EVP Valerie Morisset sold 12,342 shares of the stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $7.06, for a total value of $87,134.52. Following the sale, the executive vice president now directly owns 450,614 shares of the company’s stock, valued at $3,181,334.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 294,254 shares of company stock valued at $2,137,260 over the last quarter. Company insiders own 4.70% of the company’s stock.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.